Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Hitting the Road

(John St John/Flickr)

30 July 2015. Science and Enterprise is taking a mid-Summer break starting tomorrow, 31 July, through Monday, 3 August. We’ll resume our regular posting on Tuesday, 4 August.

* * *

Please share Science & Enterprise …

Trial Shows Weekly Growth Hormone Drug Effective, Safe

(Alkimia238/Pixabay)

30 July 2015. Results of an intermediate-stage clinical trial show a drug candidate to treat growth hormone deficiency in children given once a week, works about as well as a current therapy requiring a daily injection. The results were released by Ascendis Pharma A/S, a specialty pharmaceutical company in Copenhagen, Denmark that conducted . . . → Read More: Trial Shows Weekly Growth Hormone Drug Effective, Safe

Fibers Like Wool Yarn Devised from Animal Gelatin

Rolls of yarn made from animal gelatin (ETH Zurich)

30 July 2015. A materials science doctoral student in Switzerland developed a process for converting animal gelatin into a fiber similar to yarn from high-quality wool. Philipp Stössel, in the Functional Materials Lab at ETH Zurich, a science and technology university, led the team that . . . → Read More: Fibers Like Wool Yarn Devised from Animal Gelatin

Opioid Overdose Nasal Spray Cleared for FDA Review

(frolicsome/Pixabay)

29 July 2015. Indivior plc, a pharmaceutical company in the U.K. specializing in addiction therapies, received notice that the U.S. Food and Drug Administration accepted the company’s new drug application and is beginning review of Indivior’s opioid overdose treatment formulated as a nasal spray. The FDA also granted Indivior, in Slough, U.K., priority . . . → Read More: Opioid Overdose Nasal Spray Cleared for FDA Review

Crop Biotech Acquires Genomic Engineering Technology

Shree Krishna Dhital (Wikimedia Commons)

29 July 2015. Calyxt Inc., a biotechnology company developing new varieties of food crops, is licensing technology from University of Minnesota for more efficient modification of plant genomes. Financial details of the agreement between Calyxt, in New Brighton Minnesota, and the university were not disclosed.

Calyxt — until recently . . . → Read More: Crop Biotech Acquires Genomic Engineering Technology

Patent Awarded for Fractal Connections in Implants

Richard Taylor (University of Oregon)

28 July 2015. Electronic microcircuits designed to resemble fractals in nature used in implanted medical devices received a patent from the U.S. Patent and Trademark Office. Patent number 9,079,017 was awarded on 14 July 2015 to physicist and materials scientist Richard Taylor at University of Oregon and Simon Brown . . . → Read More: Patent Awarded for Fractal Connections in Implants

Computer Model Predicts Protein Binding to DNA, RNA

(National Heart, Lung, and Blood Institute, NIH)

28 July 2015. Geneticists and computer scientists wrote a machine-learning model for predicting the way proteins bind to genetic material, and uncovering mutations causing disease. The team led by Brendan Frey with the Canadian Institute for Advanced Research in Toronto published its findings yesterday in the journal . . . → Read More: Computer Model Predicts Protein Binding to DNA, RNA

FDA Clears Trial of Fibrosis Drug for Muscular Dystrophy

Cross-section of muscle tissue from a person with Duchenne muscular dystrophy shows extensive replacement of dark colored muscle fiber with light-colored adipose or fat cells. (Centers for Disease Control and Prevention)

24 July 2015. Biotechnology company Fibrogen Inc. says the U.S. Food and Drug Administration approved an application to test its fibrosis drug candidate . . . → Read More: FDA Clears Trial of Fibrosis Drug for Muscular Dystrophy

Allergan Acquires Depression Therapy Developer for $560M

(Lloyd Morgan, Flickr)

27 July 2015. Pharmaceutical maker Allergan plc is acquiring Naurex Inc., a designer of fast-acting therapies for depression and other neurological disorders, for $560 million. The deal covers Naurex’s products now in clinical trials, with the company’s technology platform and preclinical research spun-off into a new enterprise.

Naurex, a spin-off company . . . → Read More: Allergan Acquires Depression Therapy Developer for $560M

A Turbulent Two Days

(A. Kotok)

25 July 2015. If you tried accessing Science & Enterprise on Thursday and Friday this week, 23-24 July, you likely encountered periods when the site was not available. Please accept our sincerest apologies for the outages.

On Thursday, we ran into problems trying to update the site to the latest vesion of . . . → Read More: A Turbulent Two Days